Article
Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram.
Metabolic brain disease - 1 Jun 2012
Warwick J M, Carey P D, Cassimjee N, Lochner C, Hemmings S, Moolman-Smook H, Beetge E, Dupont P, Stein D J
Abstract excerpt
Social anxiety disorder (SAD) is characterised by fear of social or performance situations where the individual is exposed to unfamiliar people or to possible scrutiny by others. The literature on dopamine ligands and dopamine genotypes in SAD is however inconsistent. In this study we measured the effects of SSRI pharmacotherapy on dopamine transporter (DAT) binding in patients with SAD, also addressing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.